Project Grant HT94252410759
Award Date
9/15/24
Completion Date
9/14/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
This federal Project Grant award, totaling $1,009,054.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports advanced biomedical research conducted by Yale University to investigate the discovery and therapeutic targeting of endogenous retroviruses in clear cell renal cell carcinoma. The research project aims to transform healthcare for military service members and the broader public by advancing...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The federal Project Grant award of $1,356,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) aims to support the "Restoration of Clear Cell Renal Cell Carcinoma Tumorigenicity by Cell Reprogramming" research at Weill Medical College of Cornell University. The award, which runs from November 1, 2024 to October 31, 2028, will fund advanced biomedical research focused on transforming healthcare for military service members and the...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
Yale University received a $1,618,571 project grant award from the Defense Health Agency through the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
The Department of the Army Medical Command awarded a $1,339,689 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Feinstein Institutes for Medical Research. The purpose of this 4-year award, effective August 1, 2024, is to identify and functionally characterize metastasis-driving tumor cell subpopulations in localized stage III clear cell renal cell carcinoma. This research aims to transform healthcare for military service members and the broader...
This federal Project Grant award, with an ID of HT94252510644, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $1,008,999.00 award supports research conducted by Yale University to investigate the discovery and therapeutic targeting of endogenous retroviruses in clear cell renal cell carcinoma. The project aims to advance medical solutions for the military and the public by transforming healthcare through...